Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective

Department of Medicine, Wilhelminenspital, Montleartstr. 37, 1160 Vienna, Austria.
The Oncologist (Impact Factor: 4.54). 01/2010; 15(1):6-25. DOI: 10.1634/theoncologist.2009-0203
Source: PubMed

ABSTRACT The treatment of multiple myeloma (MM) has undergone significant developments in recent years. The availability of the novel agents thalidomide, bortezomib, and lenalidomide has expanded treatment options and has improved the outcome of patients with MM. Following the introduction of these agents in the relapsed/refractory setting, they are also undergoing investigation in the initial treatment of MM. A number of phase III trials have demonstrated the efficacy of novel agent combinations in the transplant and nontransplant settings, and based on these results standard induction regimens are being challenged and replaced. In the transplant setting, a number of newer induction regimens are now available that have been shown to be superior to the vincristine, doxorubicin, and dexamethasone regimen. Similarly, in the front-line treatment of patients not eligible for transplantation, regimens incorporating novel agents have been found to be superior to the traditional melphalan plus prednisone regimen. Importantly, some of the novel agents appear to be active in patients with high-risk disease, such as adverse cytogenetic features, and certain comorbidities, such as renal impairment. This review presents an overview of the most recent data with these novel agents and summarizes European treatment practices incorporating the novel agents.


Available from: Meral Beksac, May 29, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal impairment is a common complication of multiple myeloma. It is found in about 20-25% of patients at diagnosis and in up to 50% at some point during the disease course. The presence of renal insufficiency diminishes quality of life and is associated with increased mortality, although the outcomes of patients after successful induction therapy are comparable to those with normal renal function. Therefore, the treatment of multiple myeloma patients with renal impairment is a major challenge and should aim to achieve remission in a large proportion of patients. New drugs introduced to the treatment of multiple myeloma over the past decade have an established place in the treatment of patients with renal failure. Bortezomib appears to be most beneficial in this setting and in combination with other drugs gives a chance to obtain rapid remission and related improvement of renal function. Immunomodulatory drugs such as thalidomide and lenalidomide may also be used successfully in patients with renal insufficiency, although for the latter drug appropriate dose adjustments are necessary. The presence of renal failure is not a contraindication to autologous bone marrow transplantation in patients eligible for this procedure. Among the classical cytotoxic agents bendamustine should particularly be considered in patients with renal insufficiency. Appropriate supportive care is also extremely important in the management of myeloma patients with renal failure. It may include plasmapheresis and removal of free light chains with high cut-off hemodialysis, adapted dosage of bisphosphonates, and avoidance of drugs and conditions that may impair renal function.
    Clinical Lymphoma, Myeloma and Leukemia 10/2014; 15(4). DOI:10.1016/j.clml.2014.09.012 · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the last 15 years, substantial progress has been made in the treatment of patients with multiple myeloma (MM). New chemotherapeutic options with the immunomodulatory drugs thalidomide and lenalidomide and with the proteasome inhibitor bortezomib have increased the response rates before and after autologous hematopoietic stem cell transplantation (ASCT). Incorporation of the novel agents into the treatment of newly diagnosed MM and at relapse is now standard of care also for patients with MM not eligible for ASCT. However, the use of thalidomide and bortezomib is frequently associated with a dose-limiting peripheral neuropathy. In order to take full advantage of the therapeutic potential, a risk assessment for neurotoxicity is needed on a case-by-case basis. This assessment includes pre-existing neurological symptoms due to the MM, any comorbidities, and past or planned treatment regimens. The aim is to achieve maximum efficacy while minimizing the risk of developing chemotherapy-induced polyneuropathy (CIPN). This requires a neurological evaluation of the patient at regular intervals, the implementation of preventive measures, and the development of validated therapeutic strategies for emerging neurotoxic side effects. This review focuses on the incidence, prevention, and management of peripheral neurotoxicity due to thalidomide, bortezomib, and lenalidomide in the treatment of MM. © 2014 S. Karger GmbH, Freiburg.
    08/2014; 37(9):506-13. DOI:10.1159/000365534
  • [Show abstract] [Hide abstract]
    ABSTRACT: High-dose therapy followed by autologous stem cell transplantation (ASCT) has been the standard frontline consolidative therapy for patients with newly diagnosed multiple myeloma (MM) for > 2 decades. This approach has resulted in higher complete response (CR) rates and increased event-free survival and overall survival (OS) compared with conventional chemotherapy. The emergence of novel agent-based therapy combined with ASCT has revolutionized MM therapy by improving the CR rates and OS, raising questions concerning the role of hematopoietic stem cell transplantation in this setting.
    Clinical Lymphoma, Myeloma and Leukemia 07/2014; 15(2). DOI:10.1016/j.clml.2014.07.007 · 1.93 Impact Factor